We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford Immunotec and Lophius Biosciences Sign Licensing and Collaboration Agreements
News

Oxford Immunotec and Lophius Biosciences Sign Licensing and Collaboration Agreements

Oxford Immunotec and Lophius Biosciences Sign Licensing and Collaboration Agreements
News

Oxford Immunotec and Lophius Biosciences Sign Licensing and Collaboration Agreements

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford Immunotec and Lophius Biosciences Sign Licensing and Collaboration Agreements"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Immunotec will be able to develop and commercialize novel T-cell based assays using Lophius´ proprietary UREA technology in certain territories. Lophius Biosciences will be able to develop and commercialize novel T-cell based assays under a license to Oxford Immunotec's proprietary T-SPOT® technology. Financial terms were not disclosed.

Dr. Peter Wrighton-Smith, Chief Executive Officer, Oxford Immunotec commented: “We believe that Lophius’s UREA technology has distinct advantages over conventional methods of designing and producing antigens for T-cell based diagnostic test systems. We are looking forward to combining Lophius’s technology with our own, to develop and launch innovative new assays for infectious and immunological disease”.

“We are very pleased with this partnership with Oxford Immunotec, a leading company in the development of T-cell based assays, which provides us access to the T-SPOT® technology. This cooperation also confirms the commercial potential of our proprietary UREA technology platform which led to recent successful development of two CE-marked tests, namely T-Track® CMV and T-Track® EBV.” said Dr. Michael Lutz, Managing Director of Lophius Biosciences.

Advertisement